Lumentum vs GeneDx Holdings Corp — how do they compare? Lumentum trades at $1,115.27 (market cap $94.99B), while GeneDx Holdings Corp trades at $67.94 (market cap $2.02B). The key difference: Lumentum is far larger — about 47× GeneDx Holdings Corp's market cap, and GeneDx Holdings Corp is more actively traded (734,640 versus 4,855,776). Which is the better fit depends on your goals — on Pluang, investors hold Lumentum for 4 Days and GeneDx Holdings Corp for 19 Days on average.
| LITE | WGS | |
|---|---|---|
Market Cap | $94.99B | $2.02B |
Volume | 4,855,776 | 734,640 |
Sector | Technology | Health |
52-Week High | $1.13K | $167.51 |
52-Week Low | $149.61 | $34.51 |
Typical Hold Time | 4 Days | 19 Days |
Enterprise Value | $93.92B | $2.05B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
GeneDx (WGS) trades at $68.09, down 0.64% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue beating expectations but negative profitability metrics, including a -23.4% net income margin. Recent news highlights product launches and industry recognition, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth opportunity in genomic testing with strong analyst support, but faces significant execution risks from persistent losses and high valuation multiples. Key catalysts include continued revenue growth and path to profitability, while risks include competitive pressures and cash flow challenges from negative operating cash flow in 2026.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Lumentum develops photonic products, including optical components, transceivers, and lasers. Its technologies support data centers, communications networks, industrial manufacturing, and sensing applications.
Read more on LITE →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →